文献速递慢性肾脏病

非急性肾损伤的eGFR变异性对2型糖尿病且肾功能保留者CKD进展的影响

The Impact of Non-AKI eGFR Variability on CKD Progression in Individuals With Type 2 Diabetes and Preserved Kidney Function.
PubMed 文献 · Kidney Int Rep · 2026-06-18

这项全国性回顾性队列研究纳入98,322例确诊时eGFR>60 ml/min/1.73 m²且5年后仍>60的2型糖尿病患者,用线性回归残差标准差评估前5年eGFR变异性。平均随访5.1年,eGFR变异性越高,进展至G3b期CKD风险越高,多变量校正后仍显著。

要点

  • 在无AKI的T2DM且肾功能保留者中,eGFR变异性与CKD进展独立相关。
  • eGFR变异性最高四分位者进展至G3b期CKD风险是最低四分位的2.56倍。
  • 多变量校正后最高四分位vs最低四分位HR为1.57(95%CI 1.40-1.77)。

核心结论

  • 在无急性肾损伤的2型糖尿病且肾功能保留个体中,eGFR变异性与CKD进展至G3b期独立相关。

研究设计与样本

  • 全国性回顾性人群队列研究,纳入98,322例确诊时eGFR>60 ml/min/1.73 m²且5年后仍>60的2型糖尿病患者。
  • 利用确诊后前5年纵向血肌酐测量,通过线性回归模型残差标准差计算eGFR变异性。
  • 随后平均随访5.1年,用Cox比例风险模型评估eGFR变异性与进展至G3b期CKD的关联。

主要发现

  • eGFR变异性第二、三、四分位 vs 第一四分位进展至G3b期CKD的HR分别为1.56(95%CI 1.38-1.75)、1.85(95%CI 1.65-2.08)、2.56(95%CI 2.29-2.86)。
  • 多变量校正后,最高四分位 vs 最低四分位eGFR变异性的HR为1.57(95%CI 1.40-1.77)。

临床怎么用

  • 对2型糖尿病且肾功能保留者,除关注eGFR水平外,还应关注eGFR随时间的变异性以识别CKD进展高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Variability in estimated glomerular filtration rate (eGFR) has been associated with increased risks of mortality and chronic kidney disease (CKD) progression in people with type 2 diabetes mellitus (T2DM) and impaired kidney function. However, its significance in individuals with preserved kidney function remains unclear. METHODS: In this nationwide retrospective population-based study of individuals with T2DM, eGFR variability was calculated by fitting a linear regression model to longitudinal data to estimate both the individual eGFR slope over the 5-year period as well as the variability in model residuals provided by the SD of the model residuals using longitudinal serum creatinine (SCr) measurements obtained during the first 5 years after diagnosis. Cox proportional hazards models were then applied to assess the association between eGFR variability and progression to stage G3b CKD among participants with preserved kidney function. RESULTS: This study included 98,322 participants who had an eGFR > 60 ml/min per 1.73 m2 at diagnosis, remained alive with an eGFR > 60 ml/min per 1.73 m2 5 years after diagnosis, and were subsequently followed for a mean of 5.1 years. Greater eGFR variability was associated with an increased risk of progression to stage G3b CKD- hazard ratios (HRs) for the second, third, and fourth quartiles of variability versus the first quartile were 1.56 (95% confidence interval [CI]: 1.38-1.75), 1.85 (95% CI: 1.65-2.08), and 2.56 (95% CI: 2.29-2.86), respectively. This association persisted after adjustment for multiple variables-HR: 1.57; 95% CI: 1.40-1.77 for the fourth quartiles of variability versus the first quartile. CONCLUSION: eGFR variability in the absence of acute kidney injury (AKI) is associated with CKD progression in individuals with T2DM and preserved kidney function.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Hapca S, Yang Q, Li S, et al. The Impact of Non-AKI eGFR Variability on CKD Progression in Individuals With Type 2 Diabetes and Preserved Kidney Function. Kidney Int Rep. 2026. PMID: 42490958. doi:10.1016/j.ekir.2026.106667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。